The NASH monitor is part of its virology & liver diseases real world evidence portfolio which it launched in the EU5 and US last year.

Its new Japanese syndicated study will combine actual patient data with physician perceptions as well as looking at globally comparable data for cross-market comparisons.

The new therapy monitor complements Ipsos Healthcare’s existing real world evidence offer in Japan, which includes oncology, virology, autoimmune and cardiovascular diseases.

William Hall, head of Ipsos Healthcare Japan, said: “During the past 20 to 30 years, the frequency of patients presenting with non-alcoholic fatty liver diseases (NAFLD) has increased gradually in Japan in proportion to the increase in the population with lifestyle-related diseases.

“The rate of obesity in the population is not high compared to Western countries, but the incidence of NAFLD is similar to those countries. The NASH therapy monitor, now covering Japan, EU and US, will enable our clients to more clearly understand and respond to these differences.”